Health economics of diabetic foot ulcer and recent trends to accelerate treatment. (September 2022)

• Record Type: Journal Article
• Authors: Jodheea-Jutton, Abha; Hindocha, Sandip; Bhaw-Luximon, Archana
• Is Part Of: Foot. Volume 52(2022)
• Publication Date: 2022-09
• Subjects: Diabetic foot ulcer -- Health economics -- Scaffolds -- Skin substitutes -- Management; Foot -- Diseases -- Periodicals; Foot -- Surgery -- Periodicals; Foot Diseases -- Periodicals; Foot -- surgery -- Periodicals; Pied -- Maladies -- Périodiques; Pied -- Chirurgie -- Périodiques; Pied -- Lésions et blessures -- Périodiques; Foot -- Diseases; Foot -- Surgery; Periodicals; Electronic journals; Electronic journals; 617.585005
• DOI: 10.1016/j.foot.2022.101909
• Languages: English
• ISSNs: 0958-2592

Abstract

Highlights: Wide disparity in the cost and treatment of diabetic foot ulcer. Predicted health expenditure mismatch with predicted diabetic growth rate. Tissue regeneration scaffolds offer accelerated cost benefit healing. Diabetes treatment will face new unknown challenges from infectious diseases. Abstract: Diabetic foot ulcer is a preventable complication of diabetes that imposes a significant burden on the community. It leads to amputation and increased disability if left untreated and thus bears profound implications on the individual, the community and the health system at large. Diabetic foot (DF) is an area of research interest where interdisciplinary researchers are trying to elucidate the best strategy to halt the progression of chronic diabetic wounds. It is an area where tissue engineering research is making a strong impact through the use of scaffolds and skin substitutes for diabetic wound healing. This review aims at discussing the geographical health economics, its impact on healing and factors influencing financial costs of DFU. The upcoming economic and clinical impacts due to disease outbreak such as the 2020 COVID-19 has also been discussed. Finally, it will discuss novel therapy available with emphasis on skin tissue engineering scaffolds with a cost-benefit analysis. The review aims at promoting better management of people with diabetes with emphasis on emerging treatments and technologies.